King Luther Capital Management Corp held its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,470 shares of the company’s stock at the close of the second quarter. King Luther Capital Management Corp’s holdings in IDEXX Laboratories were worth $722,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Vanguard Group Inc. raised its position in IDEXX Laboratories by 24.3% in the 1st quarter. Vanguard Group Inc. now owns 8,910,555 shares of the company’s stock worth $1,377,660,000 after buying an additional 1,740,446 shares during the last quarter. BlackRock Inc. raised its position in IDEXX Laboratories by 1,967.1% in the 1st quarter. BlackRock Inc. now owns 6,427,027 shares of the company’s stock worth $993,680,000 after buying an additional 6,116,102 shares during the last quarter. State Street Corp raised its position in IDEXX Laboratories by 38.6% in the 1st quarter. State Street Corp now owns 3,911,739 shares of the company’s stock worth $604,793,000 after buying an additional 1,089,880 shares during the last quarter. Renaissance Technologies LLC raised its position in IDEXX Laboratories by 59.1% in the 1st quarter. Renaissance Technologies LLC now owns 975,600 shares of the company’s stock worth $150,838,000 after buying an additional 362,400 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in IDEXX Laboratories by 41.6% in the 1st quarter. Geode Capital Management LLC now owns 921,279 shares of the company’s stock worth $142,250,000 after buying an additional 270,871 shares during the last quarter. 87.64% of the stock is owned by institutional investors and hedge funds.

IDXX has been the subject of a number of recent analyst reports. BidaskClub lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Canaccord Genuity reissued a “buy” rating and issued a $180.00 target price on shares of IDEXX Laboratories in a research report on Tuesday, June 13th. Zacks Investment Research raised IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $177.00 target price for the company in a research report on Tuesday, June 13th. Stifel Nicolaus reissued a “buy” rating and issued a $185.00 target price on shares of IDEXX Laboratories in a research report on Friday, July 14th. Finally, CL King raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 target price for the company in a research report on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $174.00.

COPYRIGHT VIOLATION WARNING: “IDEXX Laboratories, Inc. (IDXX) Position Held by King Luther Capital Management Corp” was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/09/20/idexx-laboratories-inc-idxx-position-held-by-king-luther-capital-management-corp.html.

In other news, CEO Jonathan W. Ayers sold 18,000 shares of the firm’s stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $154.91, for a total value of $2,788,380.00. Following the completion of the transaction, the chief executive officer now directly owns 1,043,034 shares in the company, valued at $161,576,396.94. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Jonathan W. Ayers sold 17,000 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $154.54, for a total value of $2,627,180.00. Following the completion of the transaction, the chairman now owns 1,039,034 shares of the company’s stock, valued at $160,572,314.36. The disclosure for this sale can be found here. In the last three months, insiders sold 151,734 shares of company stock valued at $23,436,626. Corporate insiders own 2.77% of the company’s stock.

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at 160.53 on Wednesday. IDEXX Laboratories, Inc. has a 52-week low of $102.45 and a 52-week high of $173.01. The stock’s 50 day moving average is $154.86 and its 200 day moving average is $159.27. The stock has a market cap of $14.01 billion, a price-to-earnings ratio of 55.22 and a beta of 0.49.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.10. The business had revenue of $508.90 million during the quarter, compared to the consensus estimate of $502.44 million. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. The company’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter last year, the company earned $0.74 earnings per share. On average, equities analysts predict that IDEXX Laboratories, Inc. will post $3.18 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.